NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

AMRN

Amarin Corp ADR

May 08 • 04:00PM ET

10.71

Dollar change +0.53
Percentage change 5.21	%

Healthcare • Drug Manufacturers - General • Ireland • NASD

Peers: GILD REGN VRTX NBIX SRPT MDGL DVAX VKTX AKBA ITCI

| Held by: SPDW GWX IBBQ BIB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.27	Insider Own	0.42%	Shs Outstand	20.72M	Perf Week	-2.46%
Market Cap	221.91M	Forward P/E	-	EPS next Y	-2.33	Insider Trans	0.00%	Shs Float	20.63M	Perf Month	24.59%
Income	-87.79M	PEG	-	EPS next Q	-0.69	Inst Own	19.60%	Short Float	3.05%	Perf Quarter	-6.32%
Sales	214.21M	P/S	1.04	EPS this Y	21.75%	Inst Trans	-	Short Ratio	6.66	Perf Half Y	-11.44%
Book/sh	22.86	P/B	0.47	EPS next Y	25.67%	ROA	-12.15%	Short Interest	0.63M	Perf Year	-45.36%
Cash/sh	13.61	P/C	0.79	EPS next 5Y	25.84%	ROE	-17.22%	52W Range	7.08 - 19.45	Perf YTD	10.41%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-24.69%	ROI	-18.23%	52W High	-44.94%	Beta	0.69
Dividend TTM	-	Quick Ratio	2.55	Sales past 5Y	-8.27%	Gross Margin	33.62%	52W Low	51.27%	ATR (14)	0.88
Dividend Ex-Date	-	Current Ratio	3.53	EPS Y/Y TTM	-65.67%	Oper. Margin	-44.26%	RSI (14)	57.69	Volatility	9.05% 9.41%
Employees	275	Debt/Eq	0.02	Sales Y/Y TTM	-22.93%	Profit Margin	-40.99%	Recom	4.33	Target Price	13.50
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	-57.14%	Payout	-	Rel Volume	1.80	Prev Close	10.18
Sales Surprise	-19.14%	EPS Surprise	94.81%	Sales Q/Q	-25.33%	Earnings	May 07 BMO	Avg Volume	94.45K	Price	10.71
SMA20	5.50%	SMA50	11.78%	SMA200	-3.01%	Trades		Volume	170,092	Change	5.21%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-23	Resumed	JP Morgan	Underweight
Oct-25-23	Downgrade	Jefferies	Buy → Hold	$3 → $1
Jan-06-23	Upgrade	Jefferies	Hold → Buy	$1.30 → $3
May-06-22	Downgrade	JP Morgan	Neutral → Underweight
May-05-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$10 → $3
May-05-22	Downgrade	H.C. Wainwright	Buy → Neutral	$10 → $3
May-04-22	Downgrade	Northland Capital	Outperform → Market Perform
May-12-21	Downgrade	Goldman	Neutral → Sell	$6 → $5
Sep-29-20	Resumed	JP Morgan	Neutral
Aug-26-20	Initiated	Piper Sandler	Overweight	$21
May-05-20	Initiated	Northland Capital	Outperform	$15
Mar-31-20	Upgrade	Oppenheimer	Underperform → Perform
Mar-31-20	Downgrade	Jefferies	Buy → Hold	$30 → $4
Mar-31-20	Downgrade	Goldman	Buy → Neutral
Mar-13-20	Upgrade	Goldman	Neutral → Buy	$28
Mar-02-20	Initiated	Cowen	Outperform	$23
Feb-18-20	Upgrade	Citigroup	Neutral → Buy	$27 → $24
Jan-06-20	Initiated	JP Morgan	Neutral	$22
Dec-16-19	Downgrade	Stifel	Buy → Hold
Nov-20-19	Initiated	Oppenheimer	Underperform	$7

Show Previous Ratings

May-08-25 12:07PM	Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y (Zacks) +5.21%
03:07AM	Amarin Corp PLC (AMRN) Q1 2025 Earnings Call Highlights: Strategic Global Expansion Amidst ... (GuruFocus.com)
May-07-25 11:01AM	Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript (Seeking Alpha)
07:32AM	Amarin: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Amarin Reports First Quarter 2025 Financial Results (GlobeNewswire)
03:02AM	Loading…
May-03-25 03:02AM	Standex International Corp (SXI) Q3 2025 Earnings Call Highlights: Record Margins and Strategic ... (GuruFocus.com)
Apr-29-25 04:15PM	Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Apr-28-25 04:15PM	Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 (GlobeNewswire)
Apr-09-25 07:30AM	Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change (GlobeNewswire) +6.63%
Apr-07-25 07:30AM	Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors (GlobeNewswire)
Mar-31-25 08:00AM	Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist (GlobeNewswire)
Mar-19-25 12:45PM	Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance (Business Wire) +6.31%
07:30AM	New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo (GlobeNewswire)
Mar-13-25 03:02AM	Amarin Corp PLC (AMRN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Expanding ... (GuruFocus.com)
Mar-12-25 12:45PM	Amarin Plc (AMRN) Q4 2024 Earnings Call Transcript (Motley Fool) -14.94%
07:20AM	Loading…
07:20AM	Amarin: Q4 Earnings Snapshot (Associated Press Finance)
07:01AM	Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program (GlobeNewswire)
07:00AM	Amarin Reports Fourth Quarter Financial Results & Business Update and Announces Important Corporate Action (GlobeNewswire)
Feb-27-25 09:00AM	Amarin Marks Key Milestone for VASCEPA /VAZKEPA (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering (GlobeNewswire)
Feb-25-25 08:00AM	Amarin Receives National Reimbursement for VAZKEPA in Austria (GlobeNewswire)
Feb-19-25 08:30AM	Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025 (GlobeNewswire)
Dec-16-24 07:00AM	Amarin Receives National Reimbursement for VAZKEPA in Italy (GlobeNewswire)
Dec-13-24 09:00AM	Amarin Appoints Peter Fishman Chief Financial Officer (GlobeNewswire)
Nov-19-24 09:35AM	After Plunging -19.13% in 4 Weeks, Here's Why the Trend Might Reverse for Amarin (AMRN) (Zacks) +5.53%
Nov-11-24 08:00AM	Investigators to Present New REDUCE-IT Subanalysis of VASCEPA /VAZKEPA (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association's (AHA) Annual Scientific Sessions (GlobeNewswire)
Nov-01-24 03:19AM	Amarin Corp PLC (AMRN) Q3 2024 Earnings Call Highlights: Navigating Revenue Declines Amid ... (GuruFocus.com)
Oct-31-24 02:00AM	Amarin Plc (AMRN) Q3 2024 Earnings Call Transcript (Motley Fool)
Oct-30-24 05:21PM	Amarin: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-29-24 09:16AM	Amarin Corp PLC (AMRN) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
03:32PM	Loading…
Oct-09-24 03:32PM	Amarin Corp PLC (AMRN) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges and ... (GuruFocus.com)
Oct-01-24 08:00AM	Amarin Announces Two Upcoming Investor Events (GlobeNewswire)
Sep-09-24 07:30AM	Research Highlighting the Clinical Impact of VASCEPA /VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting (GlobeNewswire)
Aug-22-24 08:30AM	Latest Research Highlighting VASCEPA /VAZKEPA (icosapent ethyl) REDUCE-IT Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress (GlobeNewswire) -5.09%
Aug-01-24 12:59PM	Amarin (AMRN) Stock Down Despite Q2 Earnings & Revenues Beat (Zacks) -8.90%
Jul-31-24 02:15PM	Amarin Plc (AMRN) Q2 2024 Earnings Call Transcript (Motley Fool) -12.87%
07:00AM	Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-29-24 02:26PM	3 Breakthrough Stocks Under $10 Set for Massive Upside (InvestorPlace)
Jul-17-24 04:15PM	Amarin Receives National Reimbursement for VAZKEPA (icosapent ethyl) in Portugal (GlobeNewswire)
08:00AM	Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 (GlobeNewswire)
Jul-08-24 07:30AM	Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) (GlobeNewswire)
Jun-04-24 07:30AM	Amarin Board of Directors Announces CEO Transition (GlobeNewswire) -17.91%
May-28-24 08:15AM	Amarin Receives National Reimbursement for VAZKEPA (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. (GlobeNewswire)
May-06-24 08:00AM	Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference (GlobeNewswire) +7.69%
May-03-24 10:16AM	Amarin Corporation plc (NASDAQ:AMRN) Q1 2024 Earnings Call Transcript (Insider Monkey)
09:40AM	Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? (Zacks)
May-01-24 12:35PM	Amarin's (AMRN) Q1 Earnings and Revenues Surpass Estimates (Zacks) -8.86%
11:54AM	AMRN Stock Earnings: Amarin Corp Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
11:00AM	Amarin Plc (AMRN) Q1 2024 Earnings Call Transcript (Motley Fool)
08:35AM	Amarin Corp PLC (AMRN) Q1 2024 Earnings: Navigating Challenges with Strategic Focus (GuruFocus.com)
07:30AM	Amarin: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Amarin Reports First Quarter 2024 Business Update and Financial Results (GlobeNewswire)
Apr-24-24 02:00PM	Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event (GlobeNewswire)
Apr-22-24 08:00AM	Amarin Announces Results of Annual General Meeting of Shareholders (GlobeNewswire)
Apr-15-24 08:00AM	Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 (GlobeNewswire)
Apr-08-24 08:00AM	Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 (GlobeNewswire)
06:30AM	New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups (PR Newswire)
Apr-06-24 03:30PM	New REDUCE-IT Analyses Show VASCEPA /VAZKEPA (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups (GlobeNewswire)
Apr-04-24 01:20PM	Amarin (AMRN) Up 7% on Intellectual Property Wins in Europe (Zacks)
Apr-03-24 04:13PM	Why Amarin Stock Was Rocketing Higher on Wednesday (Motley Fool) +7.07%
08:00AM	Amarin Provides Update on VAZKEPA (Icosapent Ethyl) Intellectual Property Portfolio in Europe (GlobeNewswire)
Mar-25-24 08:00AM	Research Evaluating Benefits of VASCEPA/VAZKEPA (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo (GlobeNewswire)
Mar-01-24 09:30AM	Amarin's (AMRN) Q4 Earnings and Revenues Surpass Estimates (Zacks)
08:39AM	Amarin Corporation plc (NASDAQ:AMRN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 03:30PM	Amarin Plc (AMRN) Q4 2023 Earnings Call Transcript (Motley Fool) -18.94%
07:37AM	Amarin: Q4 Earnings Snapshot (Associated Press Finance)
07:34AM	Amarin Corp PLC (AMRN) Faces Revenue Decline Amidst Generic Competition (GuruFocus.com)
07:00AM	Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-15-24 08:00AM	Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 (GlobeNewswire)
Jan-22-24 07:30AM	Amarin Chairman & CEO Issue Letter to Shareholders (GlobeNewswire) +9.52%
Jan-12-24 09:40AM	Are Medical Stocks Lagging Amarin (AMRN) This Year? (Zacks)
Jan-11-24 09:34AM	Amarin (AMRN) Stock Rises on Stellar Q4 Preliminary Results (Zacks) -9.30%
Jan-10-24 07:02PM	Why Amarin Stock Skyrocketed Today (Motley Fool) +32.87%
07:00AM	Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024 (GlobeNewswire)
Dec-26-23 07:13PM	13 Most Promising Small-Cap Stocks According to Analysts (Insider Monkey)
Dec-11-23 08:00AM	Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-05-23 12:00PM	What Makes Amarin (AMRN) a New Buy Stock (Zacks)
Nov-12-23 09:00AM	New REDUCE-IT Analyses Show VASCEPA (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline (GlobeNewswire)
Nov-02-23 10:58AM	Amarin Corporation plc (NASDAQ:AMRN) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.47%
Nov-01-23 12:30PM	Amarin Plc (AMRN) Q3 2023 Earnings Call Transcript (Motley Fool)
12:03PM	Amarin (AMRN) Q3 Earnings and Revenues Surpass Estimates (Zacks)
09:30AM	Amarin (AMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
09:25AM	Amarin Corp PLC (AMRN) Reports Q3 2023 Earnings: Net Revenues Down 27% Year-Over-Year (GuruFocus.com)
07:30AM	Amarin: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Amarin Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-31-23 12:00PM	Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer (GlobeNewswire)
Oct-26-23 08:00AM	Latest Research Evaluating VASCEPA /VAZKEPA (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023 (GlobeNewswire)
Oct-23-23 10:08AM	12 Best Penny Stocks to Buy Under $1 (Insider Monkey)
Oct-19-23 08:00AM	Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023 (GlobeNewswire)
Sep-12-23 08:00AM	Amarin to Present at the 2023 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-24-23 09:29AM	11 Best Long-Term Penny Stocks to Buy Now (Insider Monkey)
Aug-19-23 11:22AM	Buffett goes big on homebuilders: Insider trades & hedge funds weekly (Investing.com)
Aug-09-23 04:05PM	Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy (GlobeNewswire)
Aug-08-23 07:00AM	Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel (GlobeNewswire)
Aug-07-23 07:00AM	Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1) (GlobeNewswire)
Aug-03-23 11:22AM	Amarin (AMRN) Q2 Earnings and Revenues Surpass Estimates (Zacks)
Aug-02-23 07:33AM	Amarin: Q2 Earnings Snapshot (AP Finance)
07:11AM	Amarin Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-31-23 08:00AM	Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea (GlobeNewswire)
Jul-28-23 02:56PM	10 Best Small Cap Pharma Stocks to Buy (Insider Monkey) +6.25%

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Berg Aaron	President and CEO	Aug 02 '24	Buy	0.64	160,000	102,400	805,380	Aug 05 05:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AMRN

Amarin Corp ADR

Upgrade your FINVIZ experience